Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12679602 | 0.93 | CYP2C9 (0.61) | CYP2C9 | |
| SCHEMBL4902738 | 0.90 | CYP2C9 (0.59) | CYP2C9 | |
| SCHEMBL4906703 | 0.90 | CYP2C9 (0.59) | CYP2C9 | |
| SCHEMBL4894584 | 0.89 | CYP2C9 (0.70) | CYP2C9 | |
| SCHEMBL12679600 | 0.88 | CYP2C9 (0.63) | CYP2C9 | |
| SCHEMBL12679605 | 0.86 | CYP2C9 (0.64) | CYP2C9 | |
| SCHEMBL12679598 | 0.85 | CYP2C9 (0.62) | CYP2C9 | |
| SCHEMBL4898781 | 0.84 | CYP2C9 (0.61) | CYP2C9 | |
| SCHEMBL12679601 | 0.83 | CYP2C9 (0.60) | CYP2C9 | |
| SCHEMBL12679597 | 0.82 | CYP2C9 (0.58) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-1745041-B1 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | GENENTECH INC (US) | 2012-06-20 | — | — | EP | disclosed |
| EP-1745041-B1 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | GENENTECH INC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1745041-A2 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | Genentech, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006078283-A2 | QUINOXALINE INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | SHH, NR4A2, NR4A3 | CYP2C9 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.